{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:24:31Z","timestamp":1790792671811,"version":"4.1.0"},"reference-count":30,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2019,9,1]]},"DOI":"10.1248\/bpb.b19-00319","type":"journal-article","created":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T22:03:05Z","timestamp":1560895385000},"page":"1450-1455","source":"Crossref","is-referenced-by-count":21,"title":["The Therapeutic Effects of Baicalin on Vitiligo Mice"],"prefix":"10.1248","volume":"42","author":[{"given":"Yiping","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Zhejiang Chinese Medical University, Third People\u2019s Hospital of Hangzhou, Hangzhou Institute of Dermatology and Venerology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangrui","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zhejiang Chinese Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zhejiang Chinese Medical University, Third People\u2019s Hospital of Hangzhou, Hangzhou Institute of Dermatology and Venerology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of the College of Pharmacy, Zhejiang Chinese Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aie","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zhejiang Chinese Medical University, Third People\u2019s Hospital of Hangzhou, Hangzhou Institute of Dermatology and Venerology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Rezaei N, Gavalas NG, Weetman AP, Kemp EH. Autoimmunity as an aetiological factor in vitiligo. J. Eur. Acad. Dermatol. Venereol.<\/i>, 21<\/b>, 865\u2013876 (2007).","DOI":"10.1111\/j.1468-3083.2007.02228.x"},{"key":"2","unstructured":"2) Palermo B, Campanelli R, Garbelli S, Mantovani S, Lantelme E, Brazzelli V, Ardig\u00f3 M, Borroni G, Martinetti M, Badulli C, Necker A, Giachino C. Specific cytotoxic T lymphocyte responses against Melan-A\/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex\/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J. Invest. Dermatol.<\/i>, 117<\/b>, 326\u2013332 (2001)."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Le Gal FA, Avril MF, Bosq J, Lefebvre P, Deschemin JC, Andrieu M, Dore MX, Guillet JG. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. J. Invest. Dermatol.<\/i>, 117<\/b>, 1464\u20131470 (2001).","DOI":"10.1046\/j.0022-202x.2001.01605.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Ogg GS, Rod Dunbar P, Romero P, Chen JL, Cerundolo V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J. Exp. Med.<\/i>, 188<\/b>, 1203\u20131208 (1998).","DOI":"10.1084\/jem.188.6.1203"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Lang KS, Caroli CC, Muhm A, Wernet D, Moris A, Schittek B, Knauss-Scherwitz E, Stevanovic S, Rammensee HG, Garbe C. HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA\/MART1. J. Invest. Dermatol.<\/i>, 116<\/b>, 891\u2013897 (2001).","DOI":"10.1046\/j.1523-1747.2001.01363.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Mandelcorn-Monson RL, Shear NH, Yau E, Sambhara S, Barber BH, Spaner D, DeBenedette MA. Cytotoxic T lymphocyte reactivity to gp100, MelanA\/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J. Invest. Dermatol.<\/i>, 121<\/b>, 550\u2013556 (2003).","DOI":"10.1046\/j.1523-1747.2003.12413.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Ibrahim HM, El-Elaimy IA, Saad Eldien HM, Badr BM, Rabah DM, Badr G. Blocking type I interferon signaling rescues lymphocytes from oxidative stress, exhaustion, and apoptosis in a streptozotocin- induced mouse model of type I diabetes. Oxid. Med. Cell. Longev.<\/i>, 2013<\/b>, 148725 (2013).","DOI":"10.1155\/2013\/148725"},{"key":"8","unstructured":"8) Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol.<\/i>, 89<\/b>, 207\u2013215 (2011)."},{"key":"9","unstructured":"9) Grimes PE, Morris R, Avaniss-Aghajani E, Soriano T, Meraz M, Metzger A. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J. Am. Acad. Dermatol.<\/i>, 51<\/b>, 52\u201361 (2004)."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Gao Z, Huang K, Xu H. Protective effects of flavonoids in the roots of Scutellaria baicalensis Georgi against hydrogen peroxide-induced oxidative stress in HS-SY5Y cells. Pharmacol. Res.<\/i>, 43<\/b>, 173\u2013178 (2001).","DOI":"10.1006\/phrs.2000.0761"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Ikezoe T, Chen SS, Heber D, Taguchi H, Koeffler HP. Baicalin is a major component of PC-SPES which inhibits the proliferation of human cancer cells via<\/i> apoptosis and cell cycle arrest. Prostate<\/i>, 49<\/b>, 285\u2013292 (2001).","DOI":"10.1002\/pros.10024"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Shen YC, Chiou WF, Chou YC, Chen CF. Mechanisms in mediating the anti-inflammatory effects of baicalin and baicalein in human leukocytes. Eur. J. Pharmacol.<\/i>, 465<\/b>, 171\u2013181 (2003).","DOI":"10.1016\/S0014-2999(03)01378-5"},{"key":"13","unstructured":"13) Rajadhyaksha M, Grossman M, Esterowitz D, Webb RH, Anderson RR. In vivo<\/i> confocal scanning laser microscopy of human skin: melanin provides strong contrast. J. Invest. Dermatol.<\/i>, 104<\/b>, 946\u2013952 (1995)."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Yamashita T, Kuwahara T, Gonza\u2019lez S, Takahashi M. Non-invasive visualization of melanin and melanocytes by reflectance-mode confocal microscopy. J. Invest. Dermatol.<\/i>, 124<\/b>, 235\u2013240 (2005).","DOI":"10.1111\/j.0022-202X.2004.23562.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Mir-Palomo S, N\u00e1cher A, Ofelia Vila Bus\u00f3 MA, Caddeo C, Manca ML, Manconi M, D\u00edez-Sales O. Baicalin and berberine ultradeformable vesicles as potential adjuvant in vitiligo therapy. Colloids Surf. B Biointerfaces<\/i>, 175<\/b>, 654\u2013662 (2019).","DOI":"10.1016\/j.colsurfb.2018.12.055"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Chen YC, Shen SC, Chen LG, Lee TJ, Yang LL. Wogonin, baicalin, and baicalein inhibition of inducible nitric oxide synthase and cyclooxygenase-2 gene expressions induced by nitric oxide synthase inhibitors and lipopolysaccharide. Biochem. Pharmacol.<\/i>, 61<\/b>, 1417\u20131427 (2001).","DOI":"10.1016\/S0006-2952(01)00594-9"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Sun J, Li L, Wu J, Liu B, Gong W, Lv Y, Luo Q, Duan X, Dong J. Effects of baicalin on airway remodeling in asthnatic mice. Planta Med.<\/i>, 79<\/b>, 199\u2013206 (2013).","DOI":"10.1055\/s-0032-1328197"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Zhu YP, Wang SQ, Xu AE. A mouse model of vitiligo induced by monobenzone. Exp. Dermatol.<\/i>, 22<\/b>, 499\u2013501 (2013).","DOI":"10.1111\/exd.12184"},{"key":"19","unstructured":"19) Grojean MF, Thivolet J, Perrot H. Acquired leukomelanoderma caused by topical depigmenting agents. Ann. Dermatol. Venereol.<\/i>, 109<\/b>, 641\u2013647 (1982)."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Badri AM, Todd PM, Garioch JJ, Gudgeon JE, Stewart DG, Goudie RB. An immunohistological study of cutaneous lymphocytes in vitiligo. J. Pathol.<\/i>, 170<\/b>, 149\u2013155 (1993).","DOI":"10.1002\/path.1711700209"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Wu J, Zhou M, Wan Y, Xu A. CD8+ T cells from vitiligo perilesional margins induce autologous melanocyte apoptosis. Mol. Med. Rep.<\/i>, 7<\/b>, 237\u2013241 (2013).","DOI":"10.3892\/mmr.2012.1117"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Lacotte S, Brun S, Muller S, Dumortier H. CXCR3, inflammation, and autoimmune diseases. Ann. N. Y. Acad. Sci.<\/i>, 1173<\/b>, 310\u2013317 (2009).","DOI":"10.1111\/j.1749-6632.2009.04813.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, Su MW, Zhou Y, Deng A, Hunter CA, Luster AD, Harris JE. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci. Transl. Med.<\/i>, 6<\/b>, 223ra23 (2014).","DOI":"10.1126\/scitranslmed.3007811"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Wang XX, Wang QQ, Wu JQ, Jiang M, Chen L, Zhang CF, Xiang LH. Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. Br. J. Dermatol.<\/i>, 174<\/b>, 1318\u20131326 (2016).","DOI":"10.1111\/bjd.14416"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Richmond JM, Bangari DS, Essien KI, Currimbhoy SD, Groom JR, Pandya AG, Youd ME, Luster AD, Harris JE. Keratinocyte-derived chemokines orchestrate T cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease. J. Invest. Dermatol.<\/i>, 137<\/b>, 350\u2013358 (2017).","DOI":"10.1016\/j.jid.2016.09.016"},{"key":"26","unstructured":"26) Moretti S, Spallanzani A, Amato L, Hautmann G, Gallerani I, Fabiani M, Fabbri P. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res.<\/i>, 15<\/b>, 87\u201392 (2002)."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Feldmann M, Brennan FM, Maini R. Cytokines in autoimmune disorders. Int. Rev. Immunol.<\/i>, 17<\/b>, 217\u2013228 (1998).","DOI":"10.3109\/08830189809084493"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Laddha NC, Dwivedi M, Begum R. Increased Tumor Necrosis Factor (TNF)-\u03b1 and its promoter polymorphisms correlate with disease progression and higher susceptibility towards vitiligo. PLOS ONE<\/i>, 7<\/b>, e52298 (2012).","DOI":"10.1371\/journal.pone.0052298"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Swope VB, Abdel-Malek Z, Kassem LM, Nordlund JJ. Interleukins1 alpha and 6 and tumor necrosis factor-alpha are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J. Invest. Dermatol.<\/i>, 96<\/b>, 180\u2013185 (1991).","DOI":"10.1111\/1523-1747.ep12460991"},{"key":"30","unstructured":"30) Zailaie MZ. Decreased proinflammatory cytokine production by peripheral blood mononuclear cells from vitiligo patients following aspirin treatment. Saudi Med. J.<\/i>, 26<\/b>, 799\u2013805 (2005)."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/42\/9\/42_b19-00319\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T03:20:34Z","timestamp":1567826434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/42\/9\/42_b19-00319\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,1]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b19-00319","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,1]]}}}